
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communication |
1 Cancer Epidemiology Centre, The Cancer Council Victoria, 2 Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, and 3 Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia; 4 Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia; 5 Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia; and 6 International Agency for Research on Cancer, Lyons, France
Requests for reprints: Gianluca Severi, Cancer Epidemiology Centre, The Cancer Council Victoria, 1 Rathdowne Street, Carlton, Victoria 3053, Australia. Phone: 61-39635-5412; Fax: 61-39635-5330. E-mail: gianluca.severi{at}cancervic.org.au
A recent study from deCode reported an association between common variants in the region 8q24 and prostate cancer risk. The strongest association was found with the single nucleotide polymorphism rs1447295. We genotyped 821 prostate cancer cases and 732 population controls for rs1447295 to test the association between this common variant and prostate cancer risk, and examine whether this association depends on Gleason score. Our case-control study confirmed the association between rs1447295 and prostate cancer risk (P = 0.0005). The odds ratio (OR) for prostate cancer was 1.52 [95% confidence interval (CI), 1.20-1.93] for carriers of any A allele compared with noncarriers. The OR for Gleason score 5 to 6 prostate cancer (1.48; 95% CI, 1.13-1.95) was similar to the OR for Gleason score 7 to 10 prostate cancer (1.58; 95% CI, 1.18-2.11, P for heterogeneity = 0.7). We conclude that the A allele of rs1447295 is associated with a higher risk of prostate cancer regardless of tumor aggressiveness, suggesting that such a variant, or a variant in linkage disequilibrium with it, plays a role early in prostate carcinogenesis. (Cancer Epidemiol Biomarkers Prev 2007;16(3):6102)
This article has been cited by other articles:
![]() |
M. Ghoussaini, H. Song, T. Koessler, A. A. Al Olama, Z. Kote-Jarai, K. E. Driver, K. A. Pooley, S. J. Ramus, S. K. Kjaer, E. Hogdall, et al. Multiple Loci With Different Cancer Specificities Within the 8q24 Gene Desert J Natl Cancer Inst, July 2, 2008; 100(13): 962 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Zheng, J. Sun, F. Wiklund, S. Smith, P. Stattin, G. Li, H.-O. Adami, F.-C. Hsu, Y. Zhu, K. Balter, et al. Cumulative Association of Five Genetic Variants with Prostate Cancer N. Engl. J. Med., February 28, 2008; 358(9): 910 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Robbins, J. B. Torres, S. Hooker, C. Bonilla, W. Hernandez, A. Candreva, C. Ahaghotu, R. Kittles, and J. Carpten Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus Genome Res., December 1, 2007; 17(12): 1717 - 1722. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Savage and M. H. Greene The Evidence for Prostate Cancer Risk Loci at 8q24 Grows Stronger J Natl Cancer Inst, October 17, 2007; 99(20): 1499 - 1501. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |